Lucid Diagnostics to Participate in Upcoming Investor Conferences

Lucid Diagnostics to Participate in Upcoming Investor Conferences

, / PRNewswire / -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences:

11 th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings : August 10, 2026

Location : Virtual

Canaccord Genuity 46 th Annual Growth Conference

Fireside Chat : August 11, 2026, at 11:30 AM ET

Location : Boston, MA

The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .

SOURCE Lucid Diagnostics

For further information: INVESTOR AND MEDIA CONTACT: Matt Riley, Vice President, Investor Relations, PAVmed Inc. & Lucid Diagnostics, mjr@pavmed.com